BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baddley J, Cantini F, Goletti D, Gómez-reino J, Mylonakis E, San-juan R, Fernández-ruiz M, Torre-cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection 2018;24:S10-20. [DOI: 10.1016/j.cmi.2017.12.025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Allen V, Longley N. Infections in Immunosuppressed Travellers with Autoimmune Inflammatory Diseases-A Narrative Review and Advice for Clinical Practice. Rheumatology (Oxford) 2021:keab445. [PMID: 34022043 DOI: 10.1093/rheumatology/keab445] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
4 Buitrago MJ, Martín-Gómez MT. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. Front Microbiol 2020;11:467. [PMID: 32269555 DOI: 10.3389/fmicb.2020.00467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
5 Imperatore N, Foggia M, Patturelli M, Rispo A, Calabrese G, Testa A, Pellegrini L, Tosone G, Di Luna I, Nardone OM, Ricciolino S, Castiglione F. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol 2021;36:1859-68. [PMID: 33283312 DOI: 10.1111/jgh.15367] [Reference Citation Analysis]
6 Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist 2020;13:513-32. [PMID: 32110062 DOI: 10.2147/IDR.S233137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Cantini F, Benucci M, Li Gobbi F, Franchi G, Niccoli L. Biosimilars for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 2019;15:1195-203. [DOI: 10.1080/1744666x.2020.1682553] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 van den Broek L, van der Werff-Ten Bosch J, Cortoos PJ, van Steijn S, van den Akker M. Severe neutropenia in a breastfed infant: a case report and discussion of the differential diagnosis. Int Med Case Rep J 2018;11:333-7. [PMID: 30532602 DOI: 10.2147/IMCRJ.S173826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Dias CF, Rigo MM, Escouto DC, Porto B, Mattiello R. Association between TNF-α and IFN-γ levels and severity of acute viral bronchiolitis. Int Rev Immunol 2021;40:433-40. [PMID: 33616469 DOI: 10.1080/08830185.2021.1889534] [Reference Citation Analysis]
10 Petersen J, Lindner C, Hakki M. Incidence and Outcomes of Bacterial Bloodstream Infections during Acute Graft-versus-Host Disease Involving the Gastrointestinal Tract after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019;25:1648-53. [PMID: 31002988 DOI: 10.1016/j.bbmt.2019.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, Aliberti S, Anzueto A, Arancibia F, Arnold F, Azoulay E, Blasi F, Bordon J, Burdette S, Cao B, Cavallazzi R, Chalmers J, Charles P, Chastre J, Claessens YE, Dean N, Duval X, Fartoukh M, Feldman C, File T, Froes F, Furmanek S, Gnoni M, Lopardo G, Luna C, Maruyama T, Menendez R, Metersky M, Mildvan D, Mortensen E, Niederman MS, Pletz M, Rello J, Restrepo MI, Shindo Y, Torres A, Waterer G, Webb B, Welte T, Witzenrath M, Wunderink R. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest 2020;158:1896-911. [PMID: 32561442 DOI: 10.1016/j.chest.2020.05.598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the Era of Targeted Therapies: Mapping the Road Ahead. Front Med (Lausanne) 2020;7:336. [PMID: 32974356 DOI: 10.3389/fmed.2020.00336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opinion on Drug Safety 2019;18:219-29. [DOI: 10.1080/14740338.2019.1577817] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
14 Hanitsch LG. [Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency]. Internist (Berl) 2022. [PMID: 35412057 DOI: 10.1007/s00108-022-01326-8] [Reference Citation Analysis]
15 Classen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021;100:1603-20. [PMID: 33846857 DOI: 10.1007/s00277-021-04452-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Fernández-ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado J, Delaloye J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection 2018;24:S2-9. [DOI: 10.1016/j.cmi.2018.01.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
17 Ward RA, Aghaeepour N, Bhattacharyya RP, Clish CB, Gaudillière B, Hacohen N, Mansour MK, Mudd PA, Pasupneti S, Presti RM, Rhee EP, Sen P, Spec A, Tam JM, Villani AC, Woolley AE, Hsu JL, Vyas JM. Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease. Open Forum Infect Dis 2021;8:ofab483. [PMID: 34805429 DOI: 10.1093/ofid/ofab483] [Reference Citation Analysis]
18 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Valentin J, Drak Alsibai K, Bertin C, Couppie P, Blaizot R. Infliximab in leprosy type 1 reaction: a case report. Int J Dermatol 2021. [PMID: 33959960 DOI: 10.1111/ijd.15645] [Reference Citation Analysis]
20 Cuadros EN, Calzada-Hernández J, Clemente D, Martín SG, Silveira LF, Lirola-Cruz MJ, Tagarro A, Lovillo MC, Rueda RMA, López AL, Aritziturri MS, Calvo C. Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening). Eur J Pediatr 2022. [PMID: 35258699 DOI: 10.1007/s00431-022-04418-7] [Reference Citation Analysis]
21 Lacoma A, Mateo L, Blanco I, Méndez MJ, Rodrigo C, Latorre I, Villar-Hernandez R, Domínguez J, Prat C. Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections. Front Immunol 2019;10:1013. [PMID: 31134083 DOI: 10.3389/fimmu.2019.01013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781-91. [PMID: 30198355 DOI: 10.1080/14787210.2018.1521270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
23 Brown RA, Barbar-Smiley F, Yildirim-Toruner C, Ardura MI, Ardoin SP, Akoghlanian S. Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. Pediatr Rheumatol Online J 2021;19:84. [PMID: 34098976 DOI: 10.1186/s12969-021-00581-7] [Reference Citation Analysis]
24 Candel FJ, Peñuelas M, Tabares C, Garcia-Vidal C, Matesanz M, Salavert M, Rivas P, Pemán J. Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. Rev Iberoam Micol 2020;37:5-16. [PMID: 31843275 DOI: 10.1016/j.riam.2019.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
26 Lin CT, Huang WN, Tsai WC, Chen JP, Hung WT, Hsieh TY, Chen HH, Hsieh CW, Lai KL, Tang KT, Tseng CW, Chen DY, Chen YH, Chen YM. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry. PLoS One 2021;16:e0250877. [PMID: 33930048 DOI: 10.1371/journal.pone.0250877] [Reference Citation Analysis]
27 Peng Y, Meng L, Hu X, Han Z, Hong Z. Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review. Infect Drug Resist 2020;13:3309-16. [PMID: 33061478 DOI: 10.2147/IDR.S267997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, Goletti D. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. J Infect 2019;79:15-23. [PMID: 30981891 DOI: 10.1016/j.jinf.2019.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
30 Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 2020;79:1532-43. [PMID: 32963049 DOI: 10.1136/annrheumdis-2020-217092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
31 Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Mem Inst Oswaldo Cruz 2020;115:e200430. [PMID: 33053052 DOI: 10.1590/0074-02760200430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
32 Flandre TD, Piaia A, Cary MG. Biologic Immunomodulatory Drugs and Infection in the Respiratory Tract of Nonhuman Primates. Toxicol Pathol 2021;49:397-407. [PMID: 32873219 DOI: 10.1177/0192623320946705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Skuhala T, Atelj A, Prepolec J, Al-Mufleh M, Stanimirović A, Vukelić D. A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage. BMC Infect Dis 2019;19:127. [PMID: 30732563 DOI: 10.1186/s12879-019-3768-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Cento V, Alteri C, Mancini V, Gatti M, Lepera V, Mazza E, Moioli MC, Merli M, Colombo J, Orcese CA, Bielli A, Torri S, Gasparini LE, Vismara C, De Gasperi A, Brioschi P, Puoti M, Cairoli R, Lombardi G, Perno CF. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. Mycoses 2020;63:1299-310. [PMID: 32810888 DOI: 10.1111/myc.13170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Senchyna F, Hogan CA, Murugesan K, Moreno A, Ho DY, Subramanian A, Schwenk HT, Budvytiene I, Costa HA, Gombar S, Banaei N. Clinical Accuracy and Impact of Plasma Cell-Free DNA Fungal PCR Panel for Non-Invasive Diagnosis of Fungal Infection. Clin Infect Dis 2021:ciab158. [PMID: 33606010 DOI: 10.1093/cid/ciab158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wu XN, Lightman S, Tomkins‐netzer O. Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review. Clin Experiment Ophthalmol 2019;47:381-95. [DOI: 10.1111/ceo.13500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
37 Ostrov BE, Amsterdam D. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases. Immunol Invest 2021;50:833-56. [PMID: 33941025 DOI: 10.1080/08820139.2021.1900863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sartori NS, Picon P, Papke A, Neyeloff JL, da Silva Chakr RM. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLoS One 2019;14:e0224963. [PMID: 31790428 DOI: 10.1371/journal.pone.0224963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hernanz I, Miguel Escuder L, Chamorro L, Moll-Udina A, Espinosa G, Sainz de la Maza M, Llorenç V, Adán A. Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series. Ocul Immunol Inflamm 2020;:1-6. [PMID: 33216652 DOI: 10.1080/09273948.2020.1834588] [Reference Citation Analysis]
41 Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther 2020;33:e14512. [PMID: 33166023 DOI: 10.1111/dth.14512] [Reference Citation Analysis]
42 Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther 2018;16:939-56. [PMID: 30388900 DOI: 10.1080/14787210.2018.1544490] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
43 Brito CA, Paiva JG, Pimentel FN, Guimarães RS, Moreira MR. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis 2021;80:e62. [PMID: 32546603 DOI: 10.1136/annrheumdis-2020-218171] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
44 Harries AD, Kumar AMV, Satyanarayana S, Takarinda KC, Timire C, Dlodlo RA. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med 2020;14:195-208. [PMID: 31760848 DOI: 10.1080/17476348.2020.1694907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Calvet X, Carpio D, Rodríguez-Lago I, García-Vicuña R, Barreiro-de-Acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol 2021:S0210-5705(21)00056-X. [PMID: 33640469 DOI: 10.1016/j.gastrohep.2021.01.007] [Reference Citation Analysis]
46 Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccin Immunother. 2019;15:1177-1182. [PMID: 30676860 DOI: 10.1080/21645515.2019.1574151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
47 Arbués A, Brees D, Chibout SD, Fox T, Kammüller M, Portevin D. TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis. PLoS Pathog 2020;16:e1008312. [PMID: 32069329 DOI: 10.1371/journal.ppat.1008312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
48 Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F. Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data. Ther Clin Risk Manag 2020;16:287-97. [PMID: 32368068 DOI: 10.2147/TCRM.S228880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep 2020;10:2456. [PMID: 32051458 DOI: 10.1038/s41598-020-59406-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
50 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021;53:183-189. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
51 Benamu E, Hogan CA, Gomez CA. Endemic Fungi in Transplant and Immunocompromised Hosts: Epidemiology, Diagnosis, Treatment, and Prevention. Curr Treat Options Infect Dis 2020;12:30-53. [DOI: 10.1007/s40506-020-00212-x] [Reference Citation Analysis]
52 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020;19:861-72. [PMID: 32552289 DOI: 10.1080/14740338.2020.1774550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Haddad FG, Kattan C, Kattan J. Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis? Immunotherapy 2020;12:759-62. [PMID: 32517560 DOI: 10.2217/imt-2020-0069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Rowaiye AB, Okpalefe OA, Onuh Adejoke O, Ogidigo JO, Hannah Oladipo O, Ogu AC, Oli AN, Olofinase S, Onyekwere O, Rabiu Abubakar A, Jahan D, Islam S, Dutta S, Haque M. Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. J Inflamm Res 2021;14:1487-510. [PMID: 33889008 DOI: 10.2147/JIR.S301784] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
55 Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
56 Cogen AL, Lebas E, De Barros B, Harnisch JP, Faber WR, Lockwood DN, Walker SL. Biologics in Leprosy: A Systematic Review and Case Report. Am J Trop Med Hyg 2020;102:1131-6. [PMID: 32157993 DOI: 10.4269/ajtmh.19-0616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ilan Y. Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track. J Leukoc Biol 2019;105:463-72. [PMID: 30476347 DOI: 10.1002/JLB.5RU0718-276RR] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
59 Hitzenbichler F, Mohr A, Salzberger B. [Pneumocystis jirovecii pneumonia-an opportunistic infection undergoing change]. Internist (Berl) 2019;60:669-77. [PMID: 31089770 DOI: 10.1007/s00108-019-0616-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Mohamad HE, Asker ME, Keshawy MM, Abdel Aal SM, Mahmoud YK. Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway. Eur J Pharmacol 2020;872:172959. [PMID: 32004528 DOI: 10.1016/j.ejphar.2020.172959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Nithianandan N, Loftus MJ, Johnson PDR, Charles PGP. Large paraspinal abscess as a complication of infliximab therapy in Crohn's disease. BMJ Case Rep 2019;12:e227665. [PMID: 31036734 DOI: 10.1136/bcr-2018-227665] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Noreña I, Fernández-Ruiz M, Aguado JM. Is there a real risk of bacterial infection in patients receiving targeted and biological therapies? Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30398-0. [PMID: 33339658 DOI: 10.1016/j.eimc.2020.10.019] [Reference Citation Analysis]
63 Boumaza A, Mezouar S, Bardou M, Raoult D, Mège JL, Desnues B. Tumor Necrosis Factor Inhibitors Exacerbate Whipple's Disease by Reprogramming Macrophage and Inducing Apoptosis. Front Immunol 2021;12:667357. [PMID: 34093562 DOI: 10.3389/fimmu.2021.667357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
65 Nunes H, Jeny F, Bouvry D, Uzunhan Y, Valeyre D. Indications for treatment of sarcoidosis. Curr Opin Pulm Med 2019;25:505-18. [PMID: 31365385 DOI: 10.1097/MCP.0000000000000604] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
66 Moser T, Bubel NE, Machegger L, Pikija S, Sellner J. Cerebral Vasculitis in Crohn's Disease: Always a Complication of Inflammatory Bowel Disease or Tumor Necrosis Factor–Alpha Inhibition? Inflammatory Bowel Diseases 2019;25:e160-1. [DOI: 10.1093/ibd/izz231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Bavaro DF, Fiordelisi D, Angarano G, Monno L, Saracino A. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opin Drug Saf 2020;19:817-42. [PMID: 32394759 DOI: 10.1080/14740338.2020.1767585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
68 Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
69 Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer 2019;7:239. [PMID: 31484550 DOI: 10.1186/s40425-019-0717-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
70 Besombes J, Souala F, Bouguen G, Guyader D, Grolhier C, Thibault V, Pronier C. Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report. BMC Gastroenterol 2022;22:322. [PMID: 35768794 DOI: 10.1186/s12876-022-02397-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Riestra S, Taxonera C, Zabana Y, Carpio D, Beltrán B, Mañosa M, Gutiérrez A, Barreiro-de Acosta M. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. Gastroenterol Hepatol 2021;44:51-66. [PMID: 32828562 DOI: 10.1016/j.gastrohep.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Zhang RS, Padegimas A, Murphy KM, Evans PT, Peters CJ, Domenico CM, Vidula MK, Mather PJ, Cevasco M, Cohen RB, Carver JR, O'Quinn RP. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. Cardiooncology 2021;7:13. [PMID: 33785062 DOI: 10.1186/s40959-021-00095-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
73 Krull E, Taraschi G, El Amari EB, Pellegrinelli JM, Martinez de Tejada B. Congenital toxoplasmosis after adalimumab treatment before pregnancy. J Obstet Gynaecol Res 2021. [PMID: 34382299 DOI: 10.1111/jog.14973] [Reference Citation Analysis]
74 Caldas JP, Silva-Pinto A, Faustino AS, Figueiredo P, Sarmento A, Santos L. Septic shock due to co-infection with Legionella pneumophila and Saprochaete clavata. IDCases 2022;27:e01369. [PMID: 35024339 DOI: 10.1016/j.idcr.2021.e01369] [Reference Citation Analysis]
75 Ho DY, Enriquez K, Multani A. Herpesvirus Infections Potentiated by Biologics. Infect Dis Clin North Am 2020;34:311-39. [PMID: 32444012 DOI: 10.1016/j.idc.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Ali GA, Goravey W. Primary tuberculosis cutis orificialis; a different face of the same coin. IDCases 2021;26:e01305. [PMID: 34703765 DOI: 10.1016/j.idcr.2021.e01305] [Reference Citation Analysis]
77 Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, Gras-Champel V, Masmoudi K, Bennis Y, Batteux B. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol 2021. [PMID: 33973280 DOI: 10.1111/fcp.12695] [Reference Citation Analysis]
78 Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 2019;18:415-25. [PMID: 31066297 DOI: 10.1080/14740338.2019.1612872] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
79 Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion. J Hepatol 2022:S0168-8278(22)02935-X. [PMID: 35850281 DOI: 10.1016/j.jhep.2022.07.003] [Reference Citation Analysis]
80 Depmeier C, Günthard HF, Steiner UC. [Infections during Immunosuppression]. Praxis (Bern 1994) 2018;107:689-98. [PMID: 29921180 DOI: 10.1024/1661-8157/a003003] [Reference Citation Analysis]
81 Parigi S, Licari A, Manti S, Marseglia GL, Tosca MA, Miraglia Del Giudice M, Caffarelli C, Calvani M, Martelli A, Cardinale F, Cravidi C, Duse M, Chiappini E. Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance. Acta Biomed 2020;91:e2020009. [PMID: 33004779 DOI: 10.23750/abm.v91i11-S.10311] [Reference Citation Analysis]